Association of medicare part D medication out-of-pocket costs with utilization of statin medications

Health Services Research

Volumn 48, Issue 4, 2013, Pages 1311-1333

  Karaca Mandic, Pinar ^a   Swenson, Tami ^b   Abraham, Jean M ^b   Kane, Robert L ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Medicare part D; Statins; utilization

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRESCRIPTION DRUG;

ARTICLE; BILLING AND CLAIMS; CARDIOVASCULAR RISK; COMORBIDITY; DRUG COST; DRUG UTILIZATION; HUMAN; MEDICARE; PATIENT COMPLIANCE;

MEDICARE PART D; STATINS; UTILIZATION;

AGED; CARDIOVASCULAR DISEASES; DRUG COSTS; FEMALE; FINANCING, PERSONAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICARE PART D; MEDICATION ADHERENCE; RISK FACTORS; UNITED STATES;

EID: 84879843975     PISSN: 00179124     EISSN: 14756773     Source Type: Journal    
DOI: 10.1111/1475-6773.12022     Document Type: Article

References (70)

1. Abaluck, J., and, J. Gruber,. 2011a. " Heterogeneity in Choice Inconsistencies among the Elderly: Evidence from Prescription Drug Plan Choice." American Economic Review 101 (3): 377-81.
2. Abaluck, J., and, J. Gruber,. 2011b. " Choice Inconsistencies among the Elderly: Evidence from Plan Choice in the Medicare Part D Program." American Economic Review 101 (4): 1180-210.
3. Afendulis, C. C., Y. He, A. M. Zaslavsky, and, M. E. Chernew,. 2011. " The Impact of Medicare Part D on Hospitalization Rates." Health Services Research 46 (4): 1022-38.
4. AIM-HIGH Investigators. 2011. " The Role of Niacin in Raising High-Density Lipoprotein Cholesterol to Reduce Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Optimally Treated Low-Density Lipoprotein Cholesterol: Baseline Characteristics of Study Participants. The Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) Trial." American Heart Journal 161 (3): 538-43.
5. ALLHAT Collaborative Research Group. 2002. " Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)." Journal of the American Medical Association 288 (23): 2998-3007.
6. Avorn, J., J. Monette, A. Lacour, R. L. Bohn, M. Monane, H. Moqun, and, J. LeLorier,. 1998. " Persistence of Use of Lipid-Lowering Medications: A Cross-National Study." Journal of the American Medical Association 279 (18): 1458-62.
7. Benner, J. S., R. J. Glynn, H. Mogun, P. J. Neumann, M. C. Weinstein, and, J. Avorn,. 2002. " Long-term Persistence in Use of Statin Therapy in Elderly Patients." Journal of the American Medical Association 288 (4): 455-61.
8. Cannon, C. P., E. Braunwald, C. H. McCabe, et al. 2004. " Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes." New England Journal of Medicine 350 (15): 1495-504.
9. Chandra, A., J. Gruber, and, R. McKnight,. 2010. " Patient Cost-sharing, Hospitalization Offsets, and the Design of Optimal Health Insurance for the Elderly." American Economic Review 100 (10): 193-213.
10. Chernew, M. E., I. A. Juster, M. Shah, et al. 2010. " Evidence that Value-Based Insurance Can Be Effective." Health Affairs 29 (3): 530-6.
11. Choudhry, N. K., J. Avorn, R. J. Glynn, et al. 2011. " Full Coverage for Preventive Medications after Myocardial Infarction." New England Journal of Medicine 365 (22): 2088-97.
12. Clearfield, M., J. R. Downs, S. Weis, et al. 2001. " Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): Efficacy and Tolerability of Long-Term Treatment with Lovastatin in Women." Journal of Women's Health and Gender-Based Medicine 10 (10): 971-81.
13. Cohen, J., K. Christianson, and, L. Feldman,. 2012. " Disease Management and Medication Compliance." Population Health Management 15 (1): 20-8.
14. Cole, J. A., H. Norman, L. B. Weatherby, and, A. M. Walker,. 2006. " Drug Copayment and Adherence in Chronic Heart Failure: Effect on Cost and Outcomes." Pharmacotherapy 26 (8): 1157-64.
15. Collins, R., R. Peto, and, J. Armitage,. 2002. " The MRC/BHF Heart Protection Study: Preliminary Results." International Journal of Clinical Practice 56 (1): 53-6.
16. Domino, M. E., S. C. Stearns, E. C. Norton, and, W. Yeh,. 2008. " Why Using Current Medications to Select a Medicare Part D Plan May Lead to Higher Out-of-Pocket Payments." Medical Care Research and Review 65 (1): 114-26.
17. Dowd, B., M. Maciejewski, H. O'Connor, G. Riley, and, Y. Geng,. 2010. " Health Plan Enrollment and Mortaility in the Medicare Program." Health Economics 20 (6): 645-59
18. Downs, J. R., M. Clearfield, S. Weis, et al. 1998. " Primary Prevention of Acute Coronary Events with Lovastatin in Men and Women with Average Cholesterol Levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study." Journal of the American Medical Association 279 (20): 1615-22.
19. Downs, J. R., M. Clearfield, H. A. Tyroler, et al. 2001. " Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): Additional Perspectives on Tolerability of Long-Term Treatment with Lovastatin." American Journal of Cardiology 87 (9): 1074-9.
20. Fairman, K. A., B. R. Motheral, and, R. R. Henderson,. 2003. " Retrospective, Long-term Follow-up Study of the Effect of a Three-tier Prescription Drug Copayment System on Pharmaceutical and Other Medical Utilization and Costs." Clinical Therapeutics 25 (12): 3147-61; discussion 3144-6.
21. Ford, I., H. Murray, C. J. Packard, et al. 2007. " Long-term Follow-up of the West of Scotland Coronary Prevention Study." New England Journal of Medicine 357 (15): 1477-86.
22. Fung, V., C. M. Mangione, J. Huang, et al. 2010. " Falling Into the Coverage Gap: Part D Drug Costs and Adherence for Medicare Advantage Prescription Drug Plan Beneficiaries with Diabetes." Health Services Research 45 (2): 355-75.
23. Gibson, T. B., T. L. Mark, K. Axelsen, O. Baser, D. A. Rublee, and, K. A. McGuigan,. 2006. " Impact of Statin Copayments on Adherence and Medical Care Utilization and Expenditures." American Journal of Managed Care 12 (12 SP): SP11-SP19.
24. Gibson, T. B., X. Song, B. Alemayehu, et al. 2010. " Cost Sharing, Adherence, and Health Outcomes in Patients with Diabetes." American Journal of Managed Care 16 (7): 589-600.
25. Gibson, T. B., S. Wang, E. Kelly, et al. 2011. " A Value-based Insurance Design Program At a Large Company Boosted Medication Adherence for Employees with Chronic Illnesses." Health Affairs 30 (1): 109-17.
26. Goldberg, R. B., M. J. Mellies, F. M. Sacks, et al. 1998. " Cardiovascular Events and Their Reduction with Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors with Average Cholesterol Levels: Subgroup Analyses in the cholesterol and Recurrent Events (CARE) Trial. The Care Investigators." Circulation 98 (23): 2513-9.
27. Goldman, D. P., G. F. Joyce, and, P. Karaca-Mandic,. 2006. " Varying Pharmacy Benefits with Clinical Status: The Case of Cholesterol-lowering Therapy." American Journal of Managed Care 12 (1): 21-8.
28. Goldman, D. P., G. F. Joyce, and, Y. Zheng,. 2007. " Prescription Drug Cost Sharing: Associations with Medication and Medical Utilization and Spending and Health." Journal of the American Medical Association 298 (1): 61-9.
29. Goldman, D. P., G. F. Joyce, J. J. Escarce, et al. 2004. " Pharmacy Benefits and the Use of Drugs by the Chronically Ill." Journal of the American Medical Association 291 (19): 2344-50.
30. Gu, Q., F. Zeng, B. V. Patel, and, L. C. Tripoli,. 2010. " Part D Coverage Gap and Adherence to Diabetes Medications." American Journal of Managed Care 16 (12): 911-8.
31. Hales, J. W., and, S. George,. 2010. " How the Doughnut Hole Affects Prescription Fulfillment Decisions Involving Cardiovascular Medications for Medicare Part D Enrollees." Managed Care 19 (12): 36-44.
32. Harris, B. L., A. Stergachis, and, L. D. Ried,. 1990. " The Effect of Drug Co-payments on Utilization and Cost of Pharmaceuticals in a Health Maintenance Organization." Medical Care 28 (10): 907-17.
33. Heart Protection Study Collaborative Group. 2002. " MRC/BHF Heart Protection Study of Cholesterol Lowering with Simvastatin in 20 536 High-Risk Individuals: A Randomised Placebocontrolled Trial." Lancet 360 (9326): 7-22.
34. Hoadley, J., E. Hargrave, and, K. Merrell,. 2007. Medicare Part D Formularies, 2006-2007. Menlo Park, CA: The Henry J. Kaiser Family Foundation.
35. Hoadley, J., E. Hargrave, J. Cubanski, and, T. Neuman,. 2006. An In-depth Examination of Formularies and Other Features of Medicare Drug Plans. Menlo Park, CA: The Henry J. Kaiser Family Foundation.
36. Hoadley, J., E. Hargrave, K. Merrell, and, J. L. Zhao,. 2008a. Medicare Part D Benefit Design and Formularies, 2006-2009. Menlo Park, CA: The Henry J. Kaiser Family Foundation.
37. Hoadley, J., E. Hargrave, K. Merrell, J. Cubanski, and, T. Neuman,. 2008b. Medicare Part D 2008 Data Spotlight: Formularies. Menlo Park, CA: The Henry J Kaiser Family Foundation.
38. Howell, N., R. Trotter, D. R. Mottram, and, P. H. Rowe,. 2004. " Compliance with Statins in Primary Care." The Pharmaceutical Journal 272 (7281): 23-6.
39. Hsu, J., M. Price, J. Huang, et al. 2006. " Unintended Consequences of Caps on Medicare Drug Benefits." New England Journal of Medicine 354 (22): 2349-59.
40. Hsu, J., V. Fung, M. Price, et al. 2008. " Medicare Beneficiaries' Knowledge of Part D Prescription Drug Program Benefits and Responses to Drug Costs." Journal of the American Medical Association 299 (16): 1929-36. doi: 10.1001/jama.299.16.1929
41. Insull, W., 1997. " The Problem of Compliance to Cholesterol Altering Therapy." Journal of Internal Medicine 241 (4): 317-25.
42. Joyce, G. F., J. J. Escarce, M. D. Solomon, and, D. P. Goldman,. 2002. " Employer Drug Benefit Plans and Spending on Prescription Drugs." Journal of the American Medical Association 288 (14): 1733-9.
43. Karaca-Mandic, P., G. F. Joyce, D. P. Goldman, and, M. Laouri,. 2010. " Cost Sharing, Family Health Care Burden, and the Use of Specialty Drugs for Rheumatoid Arthritis." Health Services Research 45 (5p1): 1227-50.
44. Karaca-Mandic, P., A. B. Jena, G. J. Joyce, and, D. P. Goldman,. 2012. " Out-of-Pocket Medication Costs and Use of Medications and Health Care Services among Children with Asthma." Journal of the American Medical Association 307 (12): 1284-91.
45. Ketcham, J. D., and, K. I. Simon,. 2008. " Medicare Part D's Effects on Elderly Patients' Drug Costs and Utilization." American Journal of Managed Care 14 (11 Suppl): SP14-22.
46. Kim, Y. A., A. Loucks, G. Yokoyama, et al. 2011. " Evaluation of Value-Based Insurance Design with a Large Retail Employer." American Journal of Managed Care 17 (10): 682-90.
47. Lewis, S. J., L. A. Moye, F. M. Sacks, et al. 1998. " Effect of Pravastatin on Cardiovascular Events in Older Patients with Myocardial Infarction and Cholesterol Levels in the Average Range. Results of the Cholesterol and Recurrent Events (CARE) Trial." Annals of Internal Medicine 129 (9): 681-9.
48. Lillard, L. A., J. Rogowski, and, R. Kington,. 1999. " Insurance Coverage for Prescription Drugs: Effects on Use and Expenditures in the Medicare Population." Medical Care 37 (9): 926-36.
49. Mahoney, J. J., 2005. " Reducing Patient Drug Acquisition Costs Can Lower Diabetes Health Claims." American Journal of Managed Care 11 (5 Suppl): S170-6.
50. McWilliams, J. M., A. M. Zaslavsky, and, H. A. Huskamp,. 2011. " Implementation of Medicare Part D and Nondrug Medical Spending for Elderly Adults with Limited Prior Drug Coverage." Journal of the American Medical Association 306 (4): 402-9.
51. MedPAC. 2010. Part D Payment System. Payment Basics. Washington, DC.
52. Mello, M. M., S. C. Stearns, and, E. C. Norton,. 2002. " Do Medicare HMOs Still Reduce Health Services Use after Controlling for Selection Bias? " Health Economics 11: 323-40.
53. National Cholesterol Education Program (NCEP). 2002. " Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report." Circulation 106 (25): 3143-421.
54. Pedersen, T. R.,. 1998. " Coronary Artery Disease: The Scandinavian Simvastatin Survival Study Experience." American Journal of Cardiology 82 (10B): 53T-6T.
55. Pfeffer, M. A., F. M. Sacks, L. A. Moye, et al. 1995. " Cholesterol and Recurrent Events: A Secondary Prevention Trial for Normolipidemic Patients. CARE Investigators." American Journal of Cardiology 76 (9): 98C-106C.
56. Plehn, J. F., B. R. Davis, F. M. Sacks, et al. 1999. " Reduction of Stroke Incidence after Myocardial Infarction with Pravastatin: The Cholesterol and Recurrent Events (CARE) Study. The Care Investigators." Circulation 99 (2): 216-23.
57. Pyorala, K., T. R. Pedersen, J. Kjekshus, O. Faergeman, A. G. Olsson, and, G. Thorgeirsson,. 1997. " Cholesterol Lowering with Simvastatin Improves Prognosis of Diabetic Patients with Coronary Heart Disease. A Subgroup Analysis of the Scandinavian Simvastatin Survival Study (4S)." Diabetes Care 20 (4): 614-20.
58. Raebel, M. A., T. Delate, J. L. Ellis, and, E. A. Bayliss,. 2008. " Effects of Reaching the Drug Benefit Threshold on Medicare Members' Healthcare Utilization during the First Year of Medicare Part D." Medical Care 46 (10): 1116-22.
59. Rasmussen, J. N., A. Chong, and, D. A. Alter,. 2007. " Relationship between Adherence to Evidence-Based Pharmacotherapy and Long-Term Mortality after Acute Myocardial Infarction." Journal of the American Medical Association 297 (2): 177-86.
60. Sacks, F. M., M. A. Pfeffer, L. A. Moye, et al. 1996. " The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels. Cholesterol and Recurrent Events Trial Investigators." New England Journal of Medicine 335 (14): 1001-9.
61. Schneeweiss, S., A. R. Patrick, M. Maclure, C. R. Dormuth, and, R. J. Glynn,. 2007. " Adherence to Statin Therapy under Drug Cost Sharing in Patients with and without Acute Myocardial Infarction: A Population-Based Natural Experiment." Circulation 115 (16): 2128-35.
62. Schultz, J. S., J. C. O'Donnell, K. L. McDonough, R. Sasane, and, J. Meyer,. 2005. " Determinants of Compliance with Statin Therapy and Low-Density Lipoprotein Cholesterol Goal Attainment in a Managed Care Population." American Journal of Managed Care 11 (5): 306-12.
63. Sever, P. S., B. Dahlof, N. R. Poulter, et al. 2003. " Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients Who Have Average or Lower-Than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial." Lancet 361 (9364): 1149-58.
64. Shepherd, J., S. M. Cobbe, I. Ford, et al. 1995. " Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia. West of Scotland Coronary Prevention Study Group." New England Journal of Medicine 333 (20): 1301-7.
65. Simes, R. J., I. C. Marschner, D. Hunt, et al. 2002. " Relationship between Lipid Levels and Clinical Outcomes in the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: To What Extent Is the Reduction in Coronary Events with Pravastatin Explained by On-Study Lipid Levels? " Circulation 105 (10): 1162-9.
66. Smith, D. G., 1993. " The Effects of Copayments and Generic Substitution on the Use and Costs of Prescription Drugs." Inquiry 30 (2): 189-98.
67. Sokol, M. C., K. A. McGuigan, R. R. Verbrugge, and, R. S. Epstein,. 2005. " Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost." Medical Care 43 (6): 521-30.
68. Tamblyn, R., R. Laprise, J. A. Hanley, et al. 2001. " Adverse Events Associated with Prescription Drug Cost-Sharing among Poor and Elderly Persons." Journal of the American Medical Association 285 (4): 421-9.
69. Tseng, C. W., R. H. Brook, E. Keeler, W. N. Steers, and, C. M. Mangione,. 2004. " Cost-lowering Strategies Used by Medicare Beneficiaries Who Exceed Drug Benefit Caps and Have a Gap in Drug Coverage." Journal of the American Medical Association 292 (8): 952-60.
70. Zhang, Y., J. M. Donohue, J. P. Newhouse, and, J. R. Lave,. 2009. " The Effects of the Coverage Gap on Drug Spending: A Closer Look at Medicare Part D." Health Affairs (Millwood) 28 (2): w317-25.